Monitoring Myelomatosis
- 1 January 1975
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 135 (1) , 125-130
- https://doi.org/10.1001/archinte.1975.00330010127016
Abstract
There is evidence for the value of the following tests in the diagnosis, monitoring, and prognosis of myelomatosis: (1) serum paraprotein measurements, (2) urine paraprotein (including Bence Jones) measurements, (3) serum albumin, (4) serum urea, (5) proteins in the urine other than those in 2, and (6) hemoglobin level. During treatment, increased rate of rise in 1 or 2, disproportionate increase in 2, emergence of related paraprotein, loss of 1 or 2 with reticulosarcomatous change, and monocytic leukemia suggest that more malignant subclones can emerge from the original myeloma clone, possibly due to drugs acting on DNA.This publication has 8 references indexed in Scilit:
- Multiple myeloma: Development of plasma cell sarcoma during apparently successful chemotherapyJournal of Clinical Pathology, 1973
- Three Cases of Multiple Myeloma in which the Preclinical Asymptomatic Phases Persisted Throughout 15 to 24 YearsBritish Journal of Cancer, 1971
- Urea, albumin, and response rates.BMJ, 1971
- Immunocytoma o' mice an' men.BMJ, 1971
- Immunochemical Classes of Myelomatosis. INCLUDING DATA FROM A THERAPEUTIC TRIAL CONDUCTED BY A MEDICAL RESEARCH COUNCIL WORKING PARTY*British Journal of Haematology, 1969
- Growth Rates and Responses to Treatment in Human MyelomatosisBritish Journal of Haematology, 1969
- Paraproteins, benign or malignant?BMJ, 1967
- THE FORMATION OF MYELOMA PROTEIN BY A MOUSE PLASMA CELL TUMORThe Journal of Experimental Medicine, 1958